

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
10 August 2023 (10.08.2023)



(10) International Publication Number  
**WO 2023/149970 A1**

(51) International Patent Classification:

C07K 16/18 (2006.01) G01N 33/68 (2006.01)  
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/079571

(22) International Filing Date:

09 November 2022 (09.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

|            |                               |    |
|------------|-------------------------------|----|
| 63/306,060 | 02 February 2022 (02.02.2022) | US |
| 63/269,394 | 15 March 2022 (15.03.2022)    | US |
| 63/364,617 | 12 May 2022 (12.05.2022)      | US |

(71) Applicant: **EISAI R&D MANAGEMENT CO., LTD.**  
[JP/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo,  
Ibaraki 112-8088 (JP).

(72) Inventor; and

(71) Applicant: **SWANSON, Chad** [US/US]; c/o Eisai Inc.,  
100 Tice Blvd., Woodcliff Lake, New Jersey 07677 (US).

(72) Inventors: **KOYAMA, Akihiko**; c/o Eisai Inc., 100  
Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **IRIZARRY, Michael**; c/o Eisai Inc., 100 Tice Blvd.,  
Woodcliff Lake, New Jersey 07677 (US). **KANEKIYO, Michio**; c/o Eisai Inc., 100 Tice Blvd., Woodcliff Lake,  
New Jersey 07677 (US). **KRAMER, Lynn**; c/o Eisai Inc.,  
100 Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **KAPLOW, June**; c/o Eisai Inc., 100 Tice Blvd., Wood-  
cliff Lake, New Jersey 07677 (US). **VERBEL, David**; c/  
o Eisai Inc., 100 Tice Blvd., Woodcliff Lake, New Jer-  
sey 07677 (US). **DHADDA, Shobha**; c/o Eisai Inc., 100  
Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **SACHDEV, Pallavi**; c/o Eisai Inc., 100 Tice Blvd., Wood-  
cliff Lake, New Jersey 07677 (US). **REYDERMAN, Lar-  
isa**; c/o Eisai Inc., 100 Tice Blvd., Woodcliff Lake, New  
Jersey 07677 (US). **HAYATO, Seiichi**; c/o Eisai Co. Ltd.,  
6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, Ibaraki  
112-8088 (JP). **LANDRY, Ishani**; c/o Eisai Inc., 100 Tice  
Blvd., Woodcliff Lake, New Jersey 07677 (US). **GOR-  
DON, Robert**; c/o Eisai Europe Ltd, EMEA Knowledge  
Centre, Mosquito Way, Hatfield Hertfordshire AL10 9SN  
(GB).

(74) Agent: **MACALPINE, Jill K.** et al.; Finnegan, Henderson,  
Farabow, Garrett & Dunner, LLP, 901 New York Avenue,  
NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to non-prejudicial disclosures or exceptions to lack of  
novelty (Rule 4.17(v))

Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))  
— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF TREATMENT USING P-TAU181 LEVEL

(57) Abstract: Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

WO 2023/149970 A1